Relation of asymmetrical dimethylarginine levels with renal outcomes in hypertensive patients with and without type 2 diabetes mellitus
- 1 March 2018
- journal article
- research article
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 32 (3) , 316-320
Abstract
No abstract availableKeywords
Funding Information
- Fundação de Amparo à Pesquisa do Estado de São Paulo (04/8486-0)
This publication has 32 references indexed in Scilit:
- The glomerular endotheliumCurrent Opinion in Nephrology and Hypertension, 2012
- Asymmetric Dimethylarginine and Clinical Outcomes in Chronic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2011
- Long-term Renal Outcomes of Patients With Type 1 Diabetes Mellitus and MicroalbuminuriaAn Analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications CohortMicroalbuminuria Outcomes in Type 1 DiabetesArchives of internal medicine (1960), 2011
- In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuriaKidney International, 2010
- Cellular ADMA: Regulation and actionPharmacological Research, 2009
- Plasma Concentration of Asymmetric Dimethylarginine (ADMA) Predicts Cardiovascular Morbidity and Mortality in Type 1 Diabetic Patients With Diabetic NephropathyDiabetes Care, 2008
- Asymmetrical dimethylarginine is related to renal function, chronic inflammation and macroangiopathy in patients with Type 2 diabetes and albuminuriaDiabetic Medicine, 2007
- ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney diseaseKidney International, 2006
- Screening for Type 2 DiabetesDiabetes Care, 2004
- Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64)Kidney International, 2003